High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence.

"CONFLICT OF INTEREST KA received funding from Viiv Healthcare which is not related to this project. All other authors declare there are no conflicts of interest."

"Funding information YFvdH was supported by the National Institutes of Health (NIH; grant nos K08 AI106420 and R01 AI158605). BS and TRS were supported by the NIH (Tennessee Center for AIDS Research, grant no. P30 AI110527). The project described was supported by CTSA award no. UL1 TR002243 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the NIH. KD acknowledges funding from the SA MRC (RFA‐EMU‐02‐2017), EDCTP (TMA‐2015SF‐1043, TMA‐1051‐TESAII, TMA‐CDF2015), UK Medical Research Council (MR/S03563X/1) and the Wellcome Trust (MR/S027777/1). RMW was supported by baseline funding from the SA MRC."